EPITIC
Main information
- Trade name:
- EPITIC 10 TAB
- Active ingredient:
- Lamotrigine
- Available from:
- PSYCOREM
- Dosage:
- 100MG
- Pharmaceutical form:
- TAB
- Composition:
- 10
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
3-5-2018
FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)
The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system.
FDA - U.S. Food and Drug Administration
25-4-2018
Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction
The FDA is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels. The immun...
FDA - U.S. Food and Drug Administration
10-9-2018
Lamotrigine : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation PSUSA/00001825/201711
Europe - EMA - European Medicines Agency
10-9-2018
Lamotrigine : List of nationally authorised medicinal products - PSUSA/00001825/201711
Europe - EMA - European Medicines Agency